Mizuho Securities Thinks Akebia Therapeutics’ Stock is Going to Recover

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $9.51, close to its 52-week low of $8.93.

According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.0% and a 50.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

Akebia Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.25 and a one-year low of $8.93. Currently, Akebia Therapeutics has an average volume of 484.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts